

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any Shares or other securities of the Company. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares thereby being offered.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.



VISEN Pharmaceuticals

维昇药业

(incorporated in the Cayman Islands with limited liability)

(Stock code: 2561)

CLARIFICATION ANNOUNCEMENT IN RELATION TO PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Reference is made to the prospectus dated March 13, 2025 (the “**Prospectus**”) issued by VISEN Pharmaceuticals (the “**Company**”). Terms defined in the Prospectus should have the same meanings when used herein unless the context herein otherwise requires. This announcement is published for the purpose of clarifying the principal place of business in Hong Kong as disclosed in the Prospectus.

It was noted that on pages 147 and IV-1 of the English version of the Prospectus, the principal place of business in Hong Kong shall be Room 1919, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong. Accordingly, on pages 147 and IV-1 of the Chinese version of the Prospectus, the principal place of business in Hong Kong shall be 香港銅鑼灣希慎道33號利園一期19樓1919室.

The above clarification does not affect other information contained in the English and the Chinese versions of the Prospectus. The Hong Kong Underwriting Agreement and other agreements relating to the Global Offering is still valid and legally binding.

The Board is of the view that clarification of the principal place of business of the Company will not affect the potential investors' assessment of the Company's business, operation or financial conditions, nor will it have any material effect to the Global Offering. The Board also confirms that, after having taken into account Rule 11.13 of the Listing Rules, there has been no significant change affecting any matter contained in the Prospectus and that no significant new matter has arisen, the inclusion of information in respect of which would have been required to be in the Prospectus if it had arisen before the Prospectus was issued, and therefore no supplementary prospectus is required.

By order of the Board
VISEN Pharmaceuticals
Mr. LU An-Bang
Executive Director and Chief Executive Officer

Hong Kong, March 20, 2025

As at the date of this announcement, the board of directors of the Company comprises (i) Mr. LU An-bang as executive director; (ii) Mr. Michael Wolff JENSEN, Mr. Jan Møller MIKKELSEN, Mr. FU Shan, Mr. Michael J. CHANG and Mr. CAO Yibo as non-executive directors; and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan and Ms. NI Hong as independent non-executive directors.